Abstract
We initially conducted a pilot study to evaluate the impact of botulinum toxin A (BtA)
on increased masseteric mass associated with pain. After injection we assessed its
impact on the muscle mass and the impact, if any, on reported pain, in a group of
10 patients who were refractory to conservative management. Results of this pilot
study indicated that clenched and unclenched muscle dimensions showed no significant
reduction (-0.82 clenched and −1 mm unclenched). However, what did prove to be significant was an improvement in their
pain scores as measured on a visual analogue scale (VAS). The mean VAS score before
the injection was 8.2, and at six weeks after the injection it was 1.8. Following
the pilot study we focused only on patients’ pain scores. Our main study included
48 patients (81 muscles) who suffered with pain secondary to increased masseteric
size, and had recorded their pain score out of 10 on the VAS before placement of BtA
into each affected muscle and again six weeks after the injection. Results showed
a mean pre-injection pain score of 7.9 and a mean post-injection pain score of 2.9.
Following the results of this study on reported pain alone, our Trust has allowed
funding to provide the intramuscular injection of BtA in appropriately selected patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to British Journal of Oral and Maxillofacial SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Masseteric hypertrophy?: preliminary report.Br J Oral Maxillofac Surg. 1999; 37: 405-408
- Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study.Br J Oral Maxillofac Surg. 2013; 51: 199-205
- The medical management of masseteric hypertrophy with botulinum toxin type A.Br J Oral Maxillofac Surg. 1994; 32: 26-28
- Botulinum toxin type A in the management of masseter muscle hypertrophy.J Oral Maxillofac Surg. 2005; 63: 20-24
- Masseteric muscle hypertrophy and its intraoral surgical correction.J Maxillofac Surg. 1977; 5: 28-35
- Masseteric hypertrophy: considerations regarding treatment planning decisions and introduction of a novel surgical technique.J Oral Maxillofac Surg. 2011; 69: 944-949
- Modified intraoral approach to removal of mandibular angle for correction of masseteric hypertrophy: a technical note.J Oral Maxillofac Surg. 2005; 63: 1057-1060
- Effectiveness of botulinum toxin B in the treatment of drooling.Br J Oral Maxillofac Surg. 2013; 51: 783-785
- Treatment of Frey’s syndrome with type A botulinum toxin: case report.J Oral Maxillofac Surg. 2000; 58: 1411-1414
- Botulinum toxin used to treat recurrent dislocation of the temporomandibular joint in a patient with osteoporosis.Br J Oral Maxillofac Surg. 2017; 55: e1-e2
- Kinetic and reaction pathway analysis in the application of botulinum toxin A for wound healing.J Toxicol. 2012; 2012159726
- Botulinum toxin treatment of bilateral masseteric hypertrophy.Br J Oral Maxillofac Surg. 1994; 32: 29-33
- An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse.J Neurol Sci. 1971; 14: 47-60
- Current studies on myofascial pain syndrome.Curr Pain Headache Rep. 2009; 13: 365-369
- Patient reported outcome measures: a model-based classification system for research and clinical practice.Qual Life Res. 2008; 17: 1125-1135
- A systematic review of patient self-completed questionnaires suitable for oral and maxillofacial surgery.Br J Oral Maxillofac Surg. 2010; 48: 579-590
- Content comparison of quality of life questionnaires used in head and neck cancer based on the international classification of functioning, disability and health: a systematic review.Eur Arch Otorhinolaryngol. 2008; 265: 627-637
- The provision of oral surgery services in England and Wales 1984–1991.Br Dent J. 1994; 176: 215-219
- Measurement of generic compared with disease-specific quality of life after removal of mandibular third molars: a patient-centred evaluation.Br J Oral Maxillofac Surg. 2017; 55: 274-280
- Effect of a domiciliary facial cooling system on generic quality of life after removal of mandibular third molars.Br J Oral Maxillofac Surg. 2018; 56: 315-321
Article info
Publication history
Published online: July 01, 2020
Accepted:
June 10,
2020
Received:
May 3,
2019
Identification
Copyright
© 2020 Published by Elsevier Ltd on behalf of The British Association of Oral and Maxillofacial Surgeons.
